Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling
Abstract Ciclopirox (CPX) is an antifungal drug that has recently been reported to act as a potential anticancer drug. However, the effects and underlying molecular mechanisms of CPX on glioblastoma multiforme (GBM) remain unknown. Bortezomib (BTZ) is the first proteasome inhibitor-based anticancer...
Main Authors: | Zhipeng Su, Shengnan Han, Qiumei Jin, Ningning Zhou, Junwan Lu, Fugen Shangguan, Shiyi Yu, Yongzhang Liu, Lu Wang, Jianglong Lu, Qun Li, Lin Cai, Chengde Wang, Xiaohe Tian, Lingyan Chen, Weiming Zheng, Bin Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-03-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-021-03535-9 |
Similar Items
-
A conserved motif in JNK/p38-specific MAPK phosphatases as a determinant for JNK1 recognition and inactivation
by: Xin Liu, et al.
Published: (2016-03-01) -
MAPK pathway: Potential role in glioblastoma multiforme
by: Kowthavarapu V. Krishna, et al.
Published: (2021-03-01) -
Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.
by: Yingxing Yue, et al.
Published: (2014-01-01) -
IN VITRO EFFICACY OF CICLOPIROX AGAINST CARBAPENEM RESISTANT ENTEROBACTERIACEAE
by: Maliha Ansari, et al.
Published: (2021-06-01) -
Synthetic Derivatives of Ciclopirox are Effective Inhibitors of Cryptococcus neoformans
by: Jeffrey Lin, et al.
Published: (2021-03-01)